Analysis of postoperative adjuvant therapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study. 2022

Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan. Electronic address: shinshin@med.kurume-u.ac.jp.

Gastric-type mucinous carcinoma (GAS) is a novel variant of uterine cervix mucinous carcinoma. GAS is a distinct entity that can be distinguished from typical endocervical adenocarcinoma (UEA). In Japan, postoperative adjuvant therapy for cervical cancer includes not only radiation therapy (RT) or concurrent chemoradiotherapy (CCRT) but also chemotherapy in many cases. However, no previous studies have analyzed adjuvant therapy for GAS. In the present study, we investigated the efficacy of adjuvant therapy for GAS. This was a preplanned secondary analysis of a dataset from previous nationwide, retrospective, observational study. The study population comprised women with stage I-II GAS who underwent surgery. Progression-free survival (PFS) and overall survival (OS) were compared among patients who did and did not receive adjuvant therapy using the Kaplan-Meier method. Data were analyzed for a total of 102 enrolled patients, who were classified as low- (17 patients), intermediate- (37 patients), or high risk (48 patients) based on the risk of postoperative cervical cancer recurrence. In the intermediate-risk group, median survival could not be assessed due to a lack of sufficient events, but the no-adjuvant and RT groups tended to exhibit better prognoses. In contrast, within the high-risk group, patients in the RT subgroup exhibited a trend towards better PFS and OS than those in the CCRT and chemotherapy groups. The prognosis of GAS was confirmed to be poor, even in cases of early-stage cancer and following surgical resection. Chemotherapy strategies, including CCRT as postoperative adjuvant therapy, tend to have a poor prognosis.

UI MeSH Term Description Entries
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D002288 Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed) Carcinoma, Colloid,Carcinoma, Mucinous,Adenocarcinomas, Mucinous,Carcinomas, Colloid,Carcinomas, Mucinous,Colloid Carcinoma,Colloid Carcinomas,Mucinous Adenocarcinoma,Mucinous Adenocarcinomas,Mucinous Carcinoma,Mucinous Carcinomas
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy
D059248 Chemoradiotherapy Treatment that combines chemotherapy with radiotherapy. Concurrent Chemoradiotherapy,Concomitant Chemoradiotherapy,Concomitant Radiochemotherapy,Concurrent Radiochemotherapy,Radiochemotherapy,Synchronous Chemoradiotherapy,Chemoradiotherapies,Chemoradiotherapies, Concomitant,Chemoradiotherapies, Concurrent,Chemoradiotherapies, Synchronous,Chemoradiotherapy, Concomitant,Chemoradiotherapy, Concurrent,Chemoradiotherapy, Synchronous,Concomitant Chemoradiotherapies,Concomitant Radiochemotherapies,Concurrent Chemoradiotherapies,Concurrent Radiochemotherapies,Radiochemotherapies,Radiochemotherapies, Concomitant,Radiochemotherapies, Concurrent,Radiochemotherapy, Concomitant,Radiochemotherapy, Concurrent,Synchronous Chemoradiotherapies

Related Publications

Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
April 2019, Gynecologic oncology,
Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
January 2015, International journal of clinical and experimental pathology,
Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
December 2022, Gynecologic oncology,
Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
March 2021, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
June 2018, Anticancer research,
Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
September 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
January 2018, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
February 2008, Gynecologic oncology,
Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
March 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Shin Nishio, and Koji Matsuo, and Hiroki Nasu, and Kenta Murotani, and Yoshiki Mikami, and Nobuo Yaegashi, and Toyomi Satoh, and Aikou Okamoto, and Mitsuya Ishikawa, and Tsutomu Miyamoto, and Masaki Mandai, and Kazuhiro Takehara, and Hideaki Yahata, and Munetaka Takekuma, and Kimio Ushijima
February 2020, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
Copied contents to your clipboard!